DEV

You are viewing our development site. Please share feedback with support@dosevault.ai or on our Discord server. See what is new in the changelog.

DOSEVAULT
PerformanceClinical Evidence: Moderate

CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) with amino-acid substitutions that extend its plasma half-life. It has been studied for its ability to increase GH and IGF-1 concentrations over several days following a single injection. The DAC version binds albumin, extending the active window to approximately one week.

Molecular Profile
linear
29 AA Sequence
Evidence grade (Moderate): Small clinical studies or well-designed non-RCT human research. This grade reflects the overall quality of available research on this compound and does not constitute a clinical recommendation.
CAS
863288-34-0
Mol. weight
3367.9 g/mol
Formula
C152H252N44O42
Chain length
29 aa
Sequence
Modified GRF(1-29) analog, C-terminal amide (stabilizing substitutions at positions 2, 8, 15, 27)
Onset and duration

Raises GH and IGF-1 over hours to days (longer with the DAC version); visible body-composition effects accrue over weeks.

Storage and reconstitution

Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.

Clinical Evidence

What the literature says

Scientific Overview

A tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone-releasing hormone (GHRH) analog.

Pharmacokinetics

Half-life (t½)
6 h
Approximate plasma half-life
Routes
Subcutaneous
Plasma decay
100%~3%@ 5× t½

t½ 30 min · ~3% remaining at 2.5 h

Citations (6)

  1. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatographyPubMed 2026
  2. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analogPubMed
  3. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsPubMed
  4. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogPubMed
  5. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjectsPubMed
  6. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth hormone secretion in GHRH knockout micePubMed

Last reviewed: 2026-05-09

Research Guide

How users approach this compound

The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.

Typical Dose Range Observed

100–300 mcg
subcutaneous injection

Research Protocols

Common Dosages

No DAC Protocol

100-200 mcg
1-2 times daily

“Usually stacked with 200-300mcg Ipamorelin”

Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Reported Uses

  • Studied for sustained elevation of growth hormone and IGF-1 in research settings
  • Investigated in combination with GHRP peptides for synergistic GH pulse amplification
  • Explored for potential body composition and recovery research applications

Key Research Benefits

  • Sustained GH release
  • Improved protein synthesis
  • Increased muscle mass
  • Faster recovery

Potential Side Effects

Water retention
Numbness/tingling
Headaches

Considerations and Cautions

  • Theoretical caution in active neoplastic disease
  • Limited human safety data outside research context

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

  • IGF-1: Primary downstream marker of growth-hormone-axis activity.
  • Fasting glucose / HbA1c: GH-axis stimulation can reduce insulin sensitivity over time.

Dose Calculator

Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

10 Units

or 0.10 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Quick Explainer

CJC-1295 allows for a sustained release of growth hormone over a longer period. It's often stacked with Ipamorelin to maximize the benefits of increased GH and IGF-1 levels.

Stack CJC-1295with…

Curated stacking partners researched alongside CJC-1295. Each link opens a dedicated stack page with combined benefits, side-effect overlap, and half-life considerations.

CJC-1295 by goal

Read CJC-1295's profile filtered through specific research goals.

CJC-1295 for Muscle GainCJC-1295 for Recovery

Related Tools

Not medical advice

Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.